Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment

被引：0
|
作者：
Rafael Morales-Barrera
Guillermo Villacampa
Natalia Vidal
Mariona Figols
Julia Giner
Teresa Bonfill
Cristina Suárez
Nely Díaz
Joaquín Mateo
Macarena González
Montserrat Domenech
Javier Puente
Joan Carles
机构：
[1] Vall d’Hebron Institute of Oncology,Department of Medical Oncology
[2] Vall d’ Hebron University Hospital,Oncology Data Science (OdysSey) Group
[3] Universitat Autònoma de Barcelona,Medical Oncology Department
[4] Vall d’Hebron Institute of Oncology (VHIO),Medical Oncology Department
[5] The Institute of Cancer Research,Medical Oncology
[6] Hospital Clínico San Carlos,undefined
[7] Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC),undefined
[8] CIBERONC,undefined
[9] Fundació Althaia Manresa,undefined
[10] Parc Taulí Hospital Universitari,undefined
[11] Institut d’Investigació i Innovació Parc Taulí I3PT,undefined
来源：
Clinical and Translational Oncology | 2023年 / 25卷
关键词：
Immune checkpoint inhibitors; Immune-related adverse events; Overall response rate; Survival; Urothelial carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3556 / 3564
页数：8
相关论文
共 50 条
  • [1] Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment
    Morales-Barrera, Rafael
    Villacampa, Guillermo
    Vidal, Natalia
    Figols, Mariona
    Giner, Julia
    Bonfill, Teresa
    Suarez, Cristina
    Diaz, Nely
    Mateo, Joaquin
    Gonzalez, Macarena
    Domenech, Montserrat
    Puente, Javier
    Carles, Joan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (12) : 3556 - 3564
  • [2] Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors
    Yoshikawa, Yuki
    Imamura, Michio
    Yamauchi, Masami
    Hayes, C. Nelson
    Aikata, Hiroshi
    Okamoto, Wataru
    Miyata, Yoshihiro
    Okada, Morihito
    Hattori, Noboru
    Sugiyama, Kazuhiko
    Yoshioka, Yukio
    Toratani, Shigeaki
    Takechi, Masaaki
    Ichinohe, Tatsuo
    Ueda, Tsutomu
    Takeno, Sachio
    Kobayashi, Tsuyoshi
    Ohdan, Hideki
    Teishima, Jun
    Hide, Michihiro
    Nagata, Yasushi
    Kudo, Yoshiki
    Iida, Koji
    Chayama, Kazuaki
    BMC CANCER, 2022, 22 (01)
  • [3] Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
    Das, Satya
    Johnson, Douglas B.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
  • [4] Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors
    Yuki Yoshikawa
    Michio Imamura
    Masami Yamauchi
    C. Nelson Hayes
    Hiroshi Aikata
    Wataru Okamoto
    Yoshihiro Miyata
    Morihito Okada
    Noboru Hattori
    Kazuhiko Sugiyama
    Yukio Yoshioka
    Shigeaki Toratani
    Masaaki Takechi
    Tatsuo Ichinohe
    Tsutomu Ueda
    Sachio Takeno
    Tsuyoshi Kobayashi
    Hideki Ohdan
    Jun Teishima
    Michihiro Hide
    Yasushi Nagata
    Yoshiki Kudo
    Koji Iida
    Kazuaki Chayama
    BMC Cancer, 22
  • [5] Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma
    Leucht, Katharina
    Ali, Nalyan
    Foller, Susan
    Grimm, Marc-Oliver
    CANCERS, 2022, 14 (18)
  • [6] Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
    Ng, Kennedy Yao Yi
    Tan, Sze Huey
    Tan, Jack Jie En
    Tay, Desiree Shu Hui
    Lee, Ailica Wan Xin
    Ang, Andrea Jing Shi
    Wong, Lawrence Wen Jun
    Choo, Su Pin
    Tai, David Wai-Meng
    Lee, Joycelyn Jie Xin
    LIVER CANCER, 2022, 11 (01) : 9 - 21
  • [7] Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma
    Kobayashi, Kazuo
    Suzuki, Kenichi
    Hiraide, Makoto
    Aoyama, Takeshi
    Yokokawa, Takashi
    Shikibu, Sari
    Hashimoto, Koki
    Iikura, Yusuke
    Sato, Hitoshi
    Sugiyama, Erika
    Tajima, Masataka
    Hama, Toshihiro
    ONCOLOGY, 2020, 98 (04) : 237 - 242
  • [8] Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
    Hamada, Kazuyuki
    Isobe, Junya
    Hattori, Kouya
    Hosonuma, Masahiro
    Baba, Yuta
    Murayama, Masakazu
    Narikawa, Yoichiro
    Toyoda, Hitoshi
    Funayama, Eiji
    Tajima, Kohei
    Shida, Midori
    Hirasawa, Yuya
    Tsurui, Toshiaki
    Ariizumi, Hirotsugu
    Ishiguro, Tomoyuki
    Suzuki, Risako
    Ohkuma, Ryotaro
    Kubota, Yutaro
    Sambe, Takehiko
    Tsuji, Mayumi
    Wada, Satoshi
    Kiuchi, Yuji
    Kobayashi, Shinichi
    Kuramasu, Atsuo
    Horiike, Atsushi
    Kim, Yun-Gi
    Tsunoda, Takuya
    Yoshimura, Kiyoshi
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [9] Letter regarding "Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma"
    Wang, Yinhan
    Huang, Yongfa
    Yang, Huayu
    Mao, Yilei
    LIVER CANCER, 2023, 12 (01) : 85 - 86
  • [10] Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
    Les, Inigo
    Martinez, Mireia
    Perez-Francisco, Ines
    Cabero, Maria
    Teijeira, Lucia
    Arrazubi, Virginia
    Torrego, Nuria
    Campillo-Calatayud, Ana
    Elejalde, Inaki
    Kochan, Grazyna
    Escors, David
    CANCERS, 2023, 15 (05)
12345